AIDS Res Hum Retroviruses by Hargrove, John W. et al.
Short Communication: Heightened HIV Antibody Responses in 
Postpartum Women as Exemplified by Recent Infection Assays: 
Implications for Incidence Estimates
John W. Hargrove1, Cari van Schalkwyk1, Jean H. Humphrey2, Kuda Mutasa2, Robert 
Ntozini2, Sherry Michele Owen3, Silvina Masciotra3, Bharat S. Parekh4, Yen T. Duong4, 
Trudy Dobbs4, Peter H. Kilmarx4,5, and Elizabeth Gonese5
1The South African DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis 
(SACEMA), University of Stellenbosch, Stellenbosch, South Africa
2Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe
3Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
4Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia
5Division of Global HIV and TB, Centers for Disease Control and Prevention, Harare, Zimbabwe
Abstract
Laboratory assays that identify recent HIV infections are important for assessing impacts of 
interventions aimed at reducing HIV incidence. Kinetics of HIV humoral responses can vary with 
inherent assay properties, and between HIV subtypes, populations, and physiological states. They 
are important in determining mean duration of recent infection (MDRI) for antibody-based assays 
for detecting recent HIV infections. We determined MDRIs for multi-subtype peptide representing 
subtypes B, E and D (BED)-capture enzyme immunoassay, limiting antigen (LAg), and Bio-Rad 
Avidity Incidence (BRAI) assays for 101 seroconverting postpartum women, recruited in Harare 
from 1997 to 2000 during the Zimbabwe Vitamin A for Mothers and Babies trial, comparing them 
against published MDRIs estimated from seroconverting cases in the general population. We also 
compared MDRIs for women who seroconverted either during the first 9 months, or at later stages, 
postpartum. At cutoffs (C) of 0.8 for BED, 1.5 for LAg, and 40% for BRAI, estimated MDRIs for 
postpartum mothers were 192, 104, and 144 days, 33%, 32%, and 52% lower than published 
estimates of 287, 152 and 298 days, respectively, for clade C samples from general populations. 
Point estimates of MDRI values were 7%–19% shorter for women who seroconverted in the first 9 
months postpartum than for those seroconverting later. MDRI values for three HIV incidence 
biomarkers are longer in the general population than among postpartum women, particularly those 
who recently gave birth, consistent with heightened immunological activation soon after birth. Our 
results provide a caution that MDRI may vary significantly between subjects in different 
physiological states.
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Use of laboratory methods to estimate HIV incidence rates requires, as input, the mean 
duration of recent infection (MDRI).1 A case is defined as recent when the optical density, 
or avidity index, measured using a chosen biomarker, is less than some preset cutoff (C). In 
southern Africa, MDRI values were first estimated for the multi-subtype peptide 
representing subtypes B, E and D (BED)-capture enzyme immunoassay using samples 
collected in Harare from 1997 to 2000 during the Zimbabwe Vitamin A for Mothers and 
Babies (ZVITAMBO) trial. MDRI estimates from this study were at least 35% shorter than 
the 287 (248–328) days estimated from other clade C samples.2,3 We observed similar 
differences when we evaluated the LAg and the CDC-developed Bio-Rad Avidity Incidence 
(BRAI) assay biomarkers using the same ZVITAMBO samples.4–6 Since MDRI estimates 
from our studies and published work emerge from the use of similar methodologies, and 
since several different estimation techniques produce similar results in all studies, there is no 
reason to suggest that the discrepancies are because of methodological differences.
We hypothesized that the observed discrepancies reflect, in part, particular characteristics of 
the ZVITAMBO trial participants, all postpartum women. The discrepancy is consistent with 
evidence that postpartum women exhibit elevated immunological responses, such that 
antibody levels increase more rapidly than in women who are neither pregnant nor 
postpartum.7 This hypothesis predicts that MDRI values should be lower in women who 
seroconvert soon after parturition than in those who seroconvert later. Accordingly we 
compared MDRI estimates for women seroconverting during the first 9 months postpartum, 
with those seroconverting later.
In the ZVITAMBO trial, 9562 women who tested HIV negative at recruitment, within 96 h 
of parturition, were followed up at 6 weeks, 3 months, and then at 3-month intervals for up 
to 24 months postpartum. We estimated MDRI values, using nonlinear mixed modeling for 
BED and LAg, and Turnbull survival analysis for BRAI,8 for women first testing HIV 
positive by 9 months postpartum, and others who seroconverted later. MDRI was defined 
here as the mean time during which subjects have an optical density, or avidity index, <C 
during a period T = 24 months postseroconversion. To qualify for the study, a case provided 
at least two HIV positive samples after seroconverting, with time between last negative and 
first positive HIV tests at most 120 days. All error limits are 95% confidence intervals.
At cutoff values (C) of 0.8 for BED, 1.5 for LAg, and 40% avidity index (AI) for BRAI, 
estimated MDRIs, using all seroconverting samples, were 192 (180–201; n = 96), 104 (98–
110; n = 101), and 144 (128–160; n = 96) days, respectively. These were 33%, 32%, and 
52% lower than published estimates of 287 (248–328), 152 (128–178), and 298 (262–338) 
days for respective assays of clade C samples.1,3,6 Other analyses (data not shown) showed 
that MDRIs do not differ significantly with the estimation method.
MDRI estimates are a function of the estimated time of detection and this varies depending 
on the HIV test system employed. Kassanjee et al. used a Western blot to define infection3: 
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the ZVITAMBO study employed two independent third-generation Elisa tests, with a 
Western blot tiebreaker, where Elisa results were discordant.9 These two systems have 
associated diagnostic delays that differ only by about 5 days.10 This difference is small 
compared with the differences of 154, 48, and 95 days for BRAI, LAg, and BED, 
respectively, between our estimates and those from the literature.3
When ZVITAMBO data were divided into those seroconverting in the first 9 months or at 12 
months or later postpartum, BED, LAg, and BRAI MDRIs for the former group were 185 
(176–195; n = 65), 99 (92–106; n = 70), and 139 (115–164; n = 65) days, respectively. These 
were 7%, 13%, and 19%, respectively, shorter than those for the latter group: 195 (171–231; 
n = 31), 113 (101–126; n = 31), and 171 (153–189; n = 31) days, respectively. For all chosen 
values of C, MDRI point estimates were lower for women seroconverting in the first 9 
months postpartum, although the differences were generally not significant at the 5% level 
of probability (Fig. 1). The small number of cases seroconverting >9 months postpartum 
limited the power of the statistical tests. It is noteworthy that the MDRIs for those in the late 
seroconverting group were still significantly lower than published estimates, consistent with 
the idea that their immunological responses had not returned to the levels typical of 
nonpregnant women.
Further work is required to establish more conclusively whether MDRI values for 
postpartum women are indeed systematically shorter than for other HIV positive cases in the 
population. What is clear, however, is the huge difference between our estimates and those 
from the literature. MDRI values estimated at different cutoffs (Fig. 1) emphasize that our 
MDRI point estimates, at the highest cutoffs investigated using BED and BRAI, and for LAg 
up to a cutoff of 2.0, are lower, for both subgroups analyzed, than published estimates at the 
much lower standard cutoffs.
We investigated whether the particularly short MDRI values might result from the vitamin A 
treatment given to half of the mothers. However, for ZVITAMBO participants, MDRIs for 
each of the three biomarkers differed by <10% between those receiving a large dose of 
vitamin A postpartum and those receiving a placebo: nor was there any significant difference 
between the MDRIs among primiparous and multiparous women.
Despite the tentative conclusion already reached, our findings are consistent with work 
showing that the postpartum period is characterized by heightened and activated innate and 
specific immune defenses, compared with nonpregnant women, and that these responses are 
accentuated in women who breastfeed, rather than formula feed, their infants.7 In the 
ZVITAMBO situation, where 99.1, 94.0, and 59.1% of the women breastfed their babies for 
at least 6, 12, and 18 months postpartum, it is not then surprising that we find decreased 
MDRI values for women seroconverting during the first 9 months, relative to the second 
year, postpartum.
Pregnant women exhibit immunosuppression, relative to nonpregnant women, increasing the 
tolerance to fetal antigens.11,12 This suppression involves, however, cell-mediated responses: 
it is unclear what happens to the humoral responses that would presumably affect MDRI 
levels. More work is thus required to estimate how MDRIs vary with physiological status.
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Since incidence estimates change linearly with the inverse of the MDRI, serious errors in 
MDRI estimates will lead to significant errors in incidence estimates. Using our estimate of 
196 days for the BED MDRI results in an HIV incidence, adjusted for a 4.8% false recent 
rate (FRR), of 3.5% (95% confidence interval 2.3–4.8) during the first 12 months 
postpartum in the ZVITAMBO trial. This is 34% higher than the incidence of 2.3% (1.5–
3.2), resulting from the use of the published MDRI estimate of 287 days,3 underlining the 
importance of ensuring the use of an appropriate MDRI value. The FRR was defined as the 
proportion of cases testing as recent infections, among those known to be HIV positive for 
more than 12 months
Reduced MDRIs among postpartum, compared with nonpregnant, women are consistent 
with heightened antibody responses after birth. This study provides a caution that we need to 
know how MDRIs vary by gender, physiological status, geographical region, ethnic group, 
and clade of virus.
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FIG. 1. 
Mean duration of recent infection (MDRI) for the (A) multi-subtype peptide representing 
subtypes B, E and D (BED), (B) Lag, and (C) Bio-Rad Avidity Incidence (BRAI) assays. 
MDRI plotted as a function of the preset cutoff and time since parturition when the mother 
was first diagnosed as HIV positive. MDRI estimated using nonlinear mixed modeling for 
BED and LAg, and Turnbull’s survival estimation technique for BRAI. Published MDRI 
estimates plotted for comparison.1,3 Sample sizes in text.
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